KRAS A146P

CI-VAR-00000057Explore in graph →NP_004976.2:p.Ala146ProNM_004985.4:c.436G>CClinVar 375963 CIViC 905 rs121913527

Curated evidence

Evidence by cancer (11 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–11 of 11 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm9
KRAS A146P	(oncogenic)	Oncogenic	B	Supports Oncogenicity	3	submitted	EID13020 In a systematic analysis of KRAS mutations across 2,280 KRAS-mutant colorectal cancer samples from three large clinical sequencing cohorts (DFCI, TCGA, MSKCC), KRAS A146P was confirmed as one of three… (full text at CIViC) PMID 41299036 · Navarro-Jiménez et al., 2025 · Open in CIViC	civic
KRAS A146P	(oncogenic)	Oncogenic	C	Supports Oncogenicity	3	submitted	EID13019 Edkins et al. identified KRAS c.436G>C (p.A146P) in one primary colorectal cancer, PD1978a, during sequencing of two independent colorectal cancer cohorts. Normal DNA from the same individuals was ana… (full text at CIViC) PMID 16969076 · Edkins et al., 2006 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
375963	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Multiple myeloma; RASopathy; Autoimmune lymphoproliferative syndrome type 4; Encephalocraniocutaneous lipomatosis	germline/somatic	4	Jul 03, 2025	clinvar

Malignant Neoplasm2
KRAS A146P	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID12168 KRAS A146P was tested in Novellus FACT assay to track MAPK pathway activation via foloursent tagged ERK2 translocation to the nucleus in cells transected with different mutant KRAS vectors. The amount… (full text at CIViC) PMID 34117033 · Loree et al., 2021 · Open in CIViC	civic
KRAS A146P	(oncogenic)	Oncogenic	D	Supports Oncogenicity	4	submitted	EID13018 Park et al. evaluated the transforming potential of 169 KRAS variants by introducing sequence-confirmed variant constructs into NIH 3T3 fibroblasts and performing focus-formation assays in triplicate.… (full text at CIViC) PMID 40970755 · Park et al., 2025 · Open in CIViC	civic